# IR-Med, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/IR-Med, Inc.). ## Overview IR-Med, Inc. is a U.S.-based medical technology company in the electromedical and electrotherapeutic apparatus field. Based on its filings, the company appears to be developing and commercializing medical devices and related technologies, with operations exposed to manufacturing, sourcing, and regulatory execution risks. ## Products & services • Electromedical and electrotherapeutic apparatus • Medical device development and commercialization • Device components and raw-material sourcing • Manufacturing and supply-chain coordination - **Electromedical devices** (70%) — Medical devices that use electrical or electromagnetic technology for diagnosis or therapy. - **Device development** (20%) — Engineering, prototyping, and product development activities for new medical technologies. - **Manufacturing and sourcing** (10%) — Procurement of raw materials, components, and production support for device output. - Electromedical and electrotherapeutic apparatus - Medical device development and commercialization - Device components and raw-material sourcing - Manufacturing and supply-chain coordination ## Customers IR-Med’s customers are likely healthcare providers, distributors, and other medical-device channel partners that buy specialized electromedical products for clinical use. The company’s filings also suggest exposure to international supply and market conditions, so customer demand may depend on regulatory approvals, product availability, and reimbursement or adoption dynamics. - **Healthcare providers** (primary) — Hospitals, clinics, and medical practices that buy devices for clinical diagnosis or therapy. - **Distributors and channel partners** (secondary) — Medical-device distributors that purchase inventory for resale into healthcare markets. - **International customers** (secondary) — Overseas buyers and partners whose demand is affected by trade policy, tariffs, and logistics. - Hospitals and clinics buying devices for patient care - Medical distributors reselling specialized equipment - Healthcare channel partners seeking differentiated technology - Potential international buyers affected by trade and logistics - End users needing clinically useful electrotherapeutic tools ## Geography IR-Med is headquartered in the United States, and its filings highlight exposure to U.S. trade policy and tariffs as a direct operating risk. The company also references manufacturing and development activities in countries where it or its customers operate, indicating that sourcing and supply-chain decisions may span multiple jurisdictions. - United States is the core operating and reporting base - Trade policy changes can affect imported components and costs - Supply chain may span foreign manufacturing and sourcing locations - Customer markets may include countries affected by tariffs - International logistics can influence production timing and margins ## Strategy The company’s near-term focus appears centered on advancing product development while maintaining supply continuity and managing cost pressure from tariffs and trade restrictions. Protecting margins, securing sourcing flexibility, and reducing operational disruption are important because the business depends on specialized components and timely manufacturing execution. - **Supply-chain resilience** (short-term) — Tariffs and trade tensions can raise costs or interrupt component availability. - **Product commercialization** (medium-term) — A medical-device company needs successful development and market adoption to scale. - Advance product development and commercialization - Protect margins against tariff-driven input cost inflation - Diversify sourcing to reduce supply-chain disruption - Maintain production timelines despite trade uncertainty - Support market access across domestic and international channels ## Risks IR-Med faces material exposure to tariff changes, trade restrictions, and supply-chain disruption because its products depend on sourced components and manufacturing execution. As a medical-device company, it also faces typical industry risks such as regulatory hurdles, commercialization uncertainty, and demand variability, which can delay revenue generation and pressure margins. - **Tariff-driven input cost inflation** [high] — U.S. tariffs may increase the cost of raw materials and components used in products. - **Supply-chain disruption** [high] — Escalating trade tensions can delay sourcing, production, and delivery timelines. - **Commercialization and adoption risk** [medium] — Medical-device products can face slow market acceptance and long sales cycles. - **Regulatory and compliance risk** [medium] — Electromedical products typically require approvals and ongoing compliance oversight. - Tariffs can raise component costs and compress margins - Trade tensions may disrupt supply chains and production timing - Dependence on sourced parts increases procurement risk - Medical-device commercialization may take longer than expected - Regulatory and market-access hurdles can delay adoption ## Accounting For IR-Med, the most important accounting issues are likely inventory and component-cost valuation, capitalization of development-related costs where applicable, and any provisions tied to supply-chain or regulatory matters. Because the company appears early in commercialization, investors should also watch for revenue timing, quarter-to-quarter volatility, and whether estimates around reserves or impairment become material as operations scale. - **Inventory and input-cost accounting** — Gross margin and working capital - **Revenue recognition timing** — Quarterly revenue comparability - **Development cost treatment** — Operating loss and asset balances - **Impairment and reserve estimates** — Earnings volatility - Inventory and component-cost valuation affect gross margin - Development spending may be expensed or capitalized depending on facts - Revenue timing may be uneven during commercialization - Reserves and provisions may be needed for supply or compliance issues - Impairment risk may rise if product programs underperform --- *Last updated: 2026-04-28T20:16:42.233732+00:00*